These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23414405)

  • 1. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
    Wang JW; Roden RB
    Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
    Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the monovalent to the nine-valent HPV vaccine.
    Pils S; Joura EA
    Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R; Zhai L; Tumban E
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
    Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.
    Miltz A; Price H; Shahmanesh M; Copas A; Gilson R
    PLoS One; 2014; 9(3):e90348. PubMed ID: 24595046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation prophylactic HPV vaccines: successes and challenges.
    Tyler M; Tumban E; Chackerian B
    Expert Rev Vaccines; 2014 Feb; 13(2):247-55. PubMed ID: 24350614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.
    Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G
    Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy.
    Loverro G; Di Naro E; Caringella AM; De Robertis AL; Loconsole D; Chironna M
    Sex Transm Infect; 2016 Feb; 92(1):67-9. PubMed ID: 26203116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT; Castellsagué X; Villa LL; Hildesheim A
    Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.